1116743-46-4 Usage
Description
SAR125844 is a small molecule inhibitor of the human protein tyrosine phosphatase SHP2, which is essential in regulating cell growth, differentiation, and survival. This chemical has demonstrated significant anti-cancer activity in preclinical studies, especially in cancers with dysregulated cell signaling pathways such as Ras and EGFR. SAR125844's capacity to inhibit cell proliferation and induce apoptosis in cancer cells positions it as a potential candidate for cancer therapy.
Uses
Used in Oncology:
SAR125844 is used as an anti-cancer agent for its ability to inhibit cell proliferation and induce apoptosis in cancer cells, particularly in cancers driven by dysregulated cell signaling pathways like Ras and EGFR. Its potential to enhance the anti-tumor effects of other cancer treatments makes it a promising agent for combination therapy.
Used in Drug Development for Cancer Therapy:
In the pharmaceutical industry, SAR125844 is utilized as a lead compound in the development of new cancer therapies. Its mechanism of action targeting SHP2 offers a novel approach to treating cancers that are otherwise resistant to conventional treatments. Further research and clinical trials are necessary to assess its full therapeutic potential and safety profile for use in human patients.
Check Digit Verification of cas no
The CAS Registry Mumber 1116743-46-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,1,6,7,4 and 3 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1116743-46:
(9*1)+(8*1)+(7*1)+(6*6)+(5*7)+(4*4)+(3*3)+(2*4)+(1*6)=134
134 % 10 = 4
So 1116743-46-4 is a valid CAS Registry Number.
1116743-46-4Relevant articles and documents
Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844)
Ugolini, Antonio,Kenigsberg, Mireille,Rak, Alexey,Vallée, Francois,Houtmann, Jacques,Lowinski, Maryse,Capdevila, Cécile,Khider, Jean,Albert, Eva,Martinet, Nathalie,Nemecek, Conception,Grapinet, Sandrine,Bacqué, Eric,Roesner, Manfred,Delaisi, Christine,Calvet, Loreley,Bonche, Fabrice,Semiond, Dorothée,Egile, Coumaran,Goulaouic, Hélène,Schio, Laurent
supporting information, p. 7066 - 7074 (2016/08/24)
The HGF/MET pathway is frequently activated in a variety of cancer types. Several selective small molecule inhibitors of the MET kinase are currently in clinical evaluation, in particular for NSCLC, liver, and gastric cancer patients. We report herein the
